Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

VERDAD

Financiado

Cerrado

A blood based biomarker identifying early Alzheimer Disease s pathology

Alzheimer’s Disease (AD) poses an unbearable impact in patients’ life, through progressive loss of cognitive capacities and overall quality of life. In Europe alone, there is currently a €280 bn yearly expenditure related to AD an... ver más

30/11/2021

Innovasjon Norge

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

Innovasjon Norge No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-11-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

Innovasjon Norge

2.36M€ | Lider

SULQUISA

425.87K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PDC2021-121350-I00 BIOMARCADORES PARA EL DIAGNOSTICO PRECOZ DEL DECLIVE COGNITI... 150K€ Cerrado

AD-RIDDLE REAL-WORLD IMPLEMENTATION, DEPLOYMENT AND VALIDATION OF EARL... 29M€ Cerrado

IPACBIS Identifying preclinical Alzheimer s disease in the community... 158K€ Cerrado

AD BIOMARKERS Combining sensitive biomarkers for early diagnosis of AD A... 198K€ Cerrado

RYC2021-031128-I Neuroimaging biomarkers in preclinical Alzheimer's disease 236K€ Cerrado

PSI2016-75484-R NUEVAS HERRAMIENTAS DIAGNOSTICAS DEL DETERIORO COGNITIVO: UN... 62K€ Cerrado

Duración del proyecto: 30 meses Fecha Inicio: 2019-05-24
Fecha Fin: 2021-11-30

Líder del proyecto

Innovasjon Norge No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Alzheimer’s Disease (AD) poses an unbearable impact in patients’ life, through progressive loss of cognitive capacities and overall quality of life. In Europe alone, there is currently a €280 bn yearly expenditure related to AD and ~10% of the population above 65 years old is currently affected by the disease, a figure that is expected to triple in the immediate future. No treatment alternatives are available for AD patients with diagnosed disease and the existing diagnostic tools are very time consuming and expensive (6 months / 10.000 EUR). While AD is not curable at final stages of disease, detection at early stages offer several treatment alternatives for example through counseling and/or dietary interventions. Detection and treatment of AD in its initial stages could provide major therapeutic and societal benefits. Treatment strategies at early stages could either slow down or even cure AD which would dramatically reduce the health care costs. PreDiagnostics will exploit and transfer research knowledge developed by its founders to a commercial setting and provide a diagnostic tool to identify patients at early stages before disease is evident. Through the VERDAD project, PreDiagnostics will finalize the final regulatory steps and introduce into the market a novel, accurate and cost-effective blood biomarker detection tool. This tool directly analyses the patients’ brain metabolism and detects reduced clearance of beta-amyloid which is the first step in AD pathology. The VERDAD project will allow for market introduction of a disruptive diagnostic test to identify AD decades before clinical signs are visible. This will facilitate early disease diagnosis and implementation of prevention strategies in likely patients. We have developed necessary collaborations to roll-out our diagnostic tool which will lead to major costs saving for the Health Care sector, generate new employment opportunities and in unlock a revenue stream of over €1.5bn 10-years post-Project.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores